Professor Xiaoyan Shen received her Ph.D. from Guangzhou University of Traditional Chinese Medicine in 2002. She worked as a visiting scholar in Department of Pharmacology, Shimane Medical University in Japan from 2000 to 2002, and did her postdoctoral research in Heart, Lung, and Blood Institute, National Institutes of Health in USA from 2003 to 2008. Before joining the Fudan University in 2013, she had worked in School of Pharmaceutical Sciences, Sun Yat-Sen University as a full professor for 4 years. She also serves as executive director of the Specialty Committee on Immunology of Traditional Chinese Medicine of the World Federation of Chinese Medicine Societies. Professor Shen’s current research focuses on therapeutic target and new drug discovery for immuno-inflammatory diseases.
Immuno-inflammatory Diseases; Therapeutic target Discovery and Verification; New drug development; Molecular pharmacology
Education
Sept. 1999 --- June 2002: M.D., Ph.D
Guangzhou University of Traditional Chinese Medicine, China
Sept. 1996 --- Jul. 1999: Master degree
Guangzhou University of Traditional Chinese Medicine, China
Sept. 1986 --- Jul. 1991: Bachelor degree
Nanjing University of Traditional Chinese Medicine, China
Professional Experiences
September 2013---Now: Full Professor
Department of Pharmacology, School of Pharmaceutical Sciences, Fudan University, P.R.China
January 2009---September 2013: Full Professor
Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, P.R.China
September 2003---August 2008: Visiting Scholar
Pulmonary-critical care medicine branch (Translational Medicine Branch),
National Heart, Lung and Blood institute (NHLBI),
National Institutes of Health (NIH)
July 2002---August 2003: Associate Professor
Department of Internal Medicine (6th),
The First Affiliated Hospital
Guangzhou University of Traditional Chinese Medicine
May. 2000---Jan. 2002: Visiting Researcher
Department of Pharmacology, Shimane medical University, Japan
Aug. 1991--- Aug. 1996: Clinican
Department of Internal Medicine, Tongzhou Traditional Chinese Medicine Hospital
Teaching Activities
Pharmacology
Grants & Projects
Year 2018
National Natural Science Foundation of China (No. 81573441)
Impact of targeted intervention of intestinal epithelial sorting nexin 10 on inflammatory bowel disease and molecular mechanism. 2018.1-2021.12, ￥595,000 yuan.
Year 2016
1. National Natural Science Foundation of China (No. 81573441)
Funtions of SNX10 in macrophage polarization and atherosclerosis through regulating the activity of lysosomal acid lipase. 2016.1-2019.12, ￥650,000 yuan.
2. Science and Technology Commission of Shanghai Municipality (No. 15DZ1900100)
Protective effects of Wang-Bi Tablet on bone erosion in rheumatoid arthritis. 2016.1-2018.12, ￥500,000 yuan.
Year 2014
National Natural Science Foundation of China (No. 81371923)
Functions and mechanisms of SNX10 mediated vesicle trafficking in bone destruction of rheumatoid arthrits. 2014.1-2017.12, ￥700,000 yuan.
Year 2013
National Natural Science Foundation of Guangdong Province (No. S2013010015313)
Functions and mechanisms of SNX10 mediated osteoclast activity. 2013.10-2015.10, ￥50,000 yuan.
Year 2012
National Natural Science Foundation of China (No. 81173056)
The molecular mechanism of Arf guanine nucleotide exchange factor BIG1 in target regulation of ABCA1 function. 2012.1-2015.12, ￥690,000 yuan.
Year 2011
1. National Natural Science Foundation of China (No. 31070924)
Molecular machinery of BIG2 related GABAA receptor trafficking and its signal modulation. 2011.1-2013.12, ￥340,000 yuan.
2. The Research Fund for the Doctoral Program of Higher Education of China (No. 20100171110052)
The molecular mechanism of Arf guanine nucleotide exchange factor BIG1 in target regulation of ABCA1 function. 2011.1-2013.12, ￥60,000 yuan.
3. The Projects of International Cooperation and Exchanges, Science and Technology Planning Project of Guangdong Province, China (No. 1011420600004)
Screening of the anti-rheumatic ingredient in Tongbiling. 2011.1-2012.12, ￥160,000 yuan.
Awards & Honors
Year 2005: Second Prize, Science and Technology Progress Award of Guangdong Province (The Third), “Studies on pharmacological mechanism of the Chinese medicinal herbal preparations on treatment of rheumatoid arthritis”.
Memberships
1. Vice Chairman, Chinese Medicin Research Committee of Orthopaedics and Traumatology of the Committee Chinese Soclety of Traditional Chinese Medicine.
2. Standing director, Council of Specialty Committee of Immunology of Traditional Chinese Medicine of World Federation of Chinese Medicine Societies.
3. Council Member, Shanghai Pharmacological Society
4. Committee member, Division of anti-inflammatory and immunological pharmacology，Chinese Pharmacological Society
Selected Publications（latest 5 yrs，<20 papers）
1. You Y, Li WZ, Zhang S, Hu B, Li YX, Li HD, Tang HH, Li QW, Guan YY, Liu LX, Bao WL, Shen X*. SNX10 mediates alcohol-induced liver injury and steatosis via regulating chaperone-mediated autophagy activation. J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30118-1. doi: 10.1016/j.jhep.2018.01.038. [Epub ahead of print].
2. Zhang S, Hu B, You Y, Yang Z, Liu L, Tang H, Bao W, Guan Y, Shen X*. Sorting nexin 10 acts as a tumor suppressor in tumorigenesis and progression of colorectal cancer through regulating chaperone mediated autophagy degradation of p21Cip1/WAF1. Cancer Letters 2018; 419:116-127.
3. Wang Y, Zhou C, Gao H, Li C, Li D, Liu P, Huang M, Shen X, Liu L. Therapeutic effect of Cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-STAT3 acetylation. Biochem Pharmacol. 2017;138:119-129.
4. Lu L, Zhang S, Li C, Zhou C, Li D, Liu P, Huang M, Shen X. Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation. Cell Death Dis. 2017;8(5):e2767.
5. Miao L, Shen X, Whiteman M, Xin H, Shen Y, Xin X, Moore PK, Zhu YZ. Hydrogen Sulfide Mitigates Myocardial Infarction via Promotion of Mitochondrial Biogenesis-Dependent M2 Polarization of Macrophages. Antioxid Redox Signal. 2016;25(5):268-81.
6. You Y, Zhou C, Li D, Cao ZL, Shen W, Li WZ, Zhang S, Hu B, Shen X. Sorting nexin 10 acting as a novel regulator of macrophage polarization mediates inflammatory response in experimental mouse colitis. Sci Rep. 2016;6:20630.
7. Zhou C, You Y, Shen W, Zhu YZ, Peng J, Feng HT, Wang Y, Li D, Shao WW, Li CX, Li WZ, Xu J, Shen X. Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation. Ann Rheum Dis. 2016 Jun;75(6):1211-8
8. Wang Y, Wang S, Li Y, Jiang J, Zhou C, Li C, Li D, Lu L, Liu P, Huang M, Shen X. Therapeutic effect of Cryptotanshinone on collagen-induced arthritis in rats via inhibiting nuclear factor kappa B signaling pathway. Transl Res. 2015;165(6):704-16.
9. Li C, Chen S, Yu Y, Zhou C, Wang Y, Le K, Li D, Shao W, Lu L, You Y, Peng J,Huang H, Liu P, Shen X. BIG1, a Brefeldin A-Inhibited Guanine Nucleotide-Exchange Factor, Is Required for GABA-Gated Cl(-) Influx Through Regulation of GABA (A) Receptor Trafficking. Mol Neurobiol. 2014;49(2):808-19.
10. Shao W, Li D, Peng J, Chen S, Zhou C, Cheng Z, Yu Y, Li H, Li C, You Y, Ma Y, Liu P, Yin S, Shen X. Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor β/small mother against decapentaplegic signaling pathways. Transl Res. 2014;163(2):160-70.
11. Lin S, Zhou C, Neufeld E, Wang YH, Xu SW, Lu L, Wang Y, Liu ZP, Li D, Li C, Chen S, Le K, Huang H, Liu P, Moss J, Vaughan M, Shen X* . BIG1, a brefeldin A-inhibited guanine nucleotide-exchange protein modulates ABCA1 trafficking and function. Arterioscler Thromb Vasc Biol. 2013;33(2):e31-8.
12. Li Y, Wang S, Wang Y, Zhou C, Chen G, Shen W, Li C, Lin W, Lin S, Huang H, Liu P, Shen X. Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Transl Res. 2013; 161:89-98.
13. Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, Shen XY, Ji Y. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity. Br J Pharmacol. 2013 ;168(1):117-28.
14. Xiaoyan Shen*, Li CC, Aponte AM, Shen RF, Billings EM, Moss J, Vaughan M. Brefeldin A-inhibited ADP-ribosylation factor activator BIG2 regulates cell migration via integrin β1 cycling and actin remodeling. Proc Natl Acad Sci U S A. 2012;109(36):14464-9.
